GWS
AIMT

Glassman Wealth Services’s Aimmune Therapeutics AIMT Stock Holding History

Glassman Wealth Services’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19
Closed -$1K – 1739
2019
Q4 		$1K Buy
19
+18
+1,800% +$503 ﹤0.01% 1124
2019
Q3 		$0 Buy
+1
New +$20 ﹤0.01% 1523

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Glassman Wealth Services's AIMT Position: Q1 2020 in Review

Glassman Wealth Services sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 19 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in AIMT in Q3 2019 and held it in 2 quarters. The position peaked at $1K in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Glassman Wealth Services reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Glassman Wealth Services sold 19 Aimmune Therapeutics shares in Q1 2020, an estimated $1K.
  • Glassman Wealth Services first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 2 quarters.
  • Glassman Wealth Services's Aimmune Therapeutics position peaked at $1K in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Glassman Wealth Services's 13F filing for Q1 2020, filed 12 May 2020.